Application of lactobacillus johnsonii in colorectal tumor

By using Lactobacillus johnsonii as a biomarker for colorectal tumors and adjusting the gut microbiota based on Lactobacillus johnsonii abundance, the application of Lactobacillus johnsonii in colorectal tumors was left unaddressed, providing a safe treatment option that reduces the abundance of harmful bacteria in the gut and alleviates tumor progression.

CN121380378APending Publication Date: 2026-01-23THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202410980858.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2026-01-23

AI Technical Summary

Technical Problem

There is currently no application of Lactobacillus johnsonii in colorectal cancer, and there is a lack of treatment options for healthy drug-resistant strains. Furthermore, existing treatments such as chemotherapy and radiotherapy have serious side effects.

Method used

Using low abundance of Lactobacillus johnsonii as a biomarker for colorectal tumors, the gut microbiota can be adjusted and the progression of colorectal tumors can be alleviated by using activators that increase the abundance of Lactobacillus johnsonii or by preparing bacterial preparations containing Lactobacillus johnsonii.

Benefits of technology

The abundance of Lactobacillus johnsonii is negatively correlated with the severity of colorectal tumors. The degree of tumor can be determined by adjusting the abundance of Lactobacillus johnsonii, and the tumor progression can be slowed by increasing the abundance of Lactobacillus johnsonii to reduce harmful bacteria in the intestines, thus providing a safe treatment option.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to application of lactobacillus johnsonii in colorectal tumor. According to the application, low-abundance lactobacillus johnsonii is used as a biomarker of colorectal tumors, and the abundance ratio of the low-abundance lactobacillus johnsonii to normal-abundance lactobacillus johnsonii is smaller than or equal to 0.9. Based on a large number of experiments in the early stage, the abundance of lactobacillus johnsonii in the intestinal tract of a patient with colorectal tumor shows a significant reduction trend; in addition, the abundance of the lactobacillus johnsonii in the intestinal tract of the patient with colorectal tumor is highly positively correlated with the beneficial bacterium bacteroides simplex in the intestinal tract and is negatively correlated with harmful bacteria in the intestinal tract; in addition, lactobacillus johnsonii is used for intragastric administration, and the number and the volume of tumors of a mouse with colorectal tumors are obviously reduced, so that the lactobacillus johnsonii can be used as a biomarker of the colorectal tumors, and the blank of application of the lactobacillus johnsonii in the aspect of the colorectal tumors in the prior art is filled.
Need to check novelty before this filing date? Find Prior Art